(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of 17.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Arcus Biosciences's revenue in 2025 is $141,000,000.On average, 5 Wall Street analysts forecast RCUS's revenue for 2025 to be $11,747,956,061, with the lowest RCUS revenue forecast at $9,317,892,144, and the highest RCUS revenue forecast at $16,173,954,830. On average, 5 Wall Street analysts forecast RCUS's revenue for 2026 to be $16,076,752,273, with the lowest RCUS revenue forecast at $4,658,946,072, and the highest RCUS revenue forecast at $28,536,044,691.
In 2027, RCUS is forecast to generate $24,810,687,881 in revenue, with the lowest revenue forecast at $13,320,350,360 and the highest revenue forecast at $37,186,860,466.